Rare Daily Staff
n-Lorem Foundation, a nonprofit organization that provides free, lifetime supplies of individualized RNA-targeted medicines to patients with ultra-rare diseases, said it has formed a partnership with Nitto Avecia, the world’s largest oligonucleotide therapeutics manufacturer.
Through the partnership, Nitto Avecia will provide manufacturing support through its contribution of active pharmaceutical ingredients for the development of individualized ASO medicines, as well as a financial donation to the foundation.
N-Lorem said that the partnership and resources are critical in helping n-Lorem continue to rapidly scale-up its unique charitable model to help as many patients as possible.
“We are committed to advancing the development of oligonucleotide therapeutics, and n-Lorem’s mission to bring individualized ASO treatments to patients with ultra-rare conditions falls perfectly in-line with what we’ve set out to do,” said Seiji Fujioka, president of Nitto Avecia.
Photo: Seiji Fujioka, president of Nitto Avecia